The region’s health departments are bracing for a roughly 85% decrease in doses of one type of COVID vaccine between this week and next.

Maryland is likely to receive only 11,000 Johnson & Johnson single-dose vaccines next week, compared to the 89,000 it received this week. Virginia is expecting to receive 14,800 vaccines, compared to the 124,000 it received this week. And, the District will receive around 1,300 next week, compared to the 10,800 from this week. The shortage is “likely” due to the 15 million botched doses of the Johnson & Johnson vaccine at their manufacturing plant in Baltimore, according to Dr. Travis Gayles, Montgomery County’s health officer.

“We are entirely dependent on weekly allocations from the federal government, which we have consistently been told would either remain stable or increase,” Dennis Schrader, the state’s health secretary, said in a statement to vaccine providers earlier in the week.

The decline comes after a batch of vaccines had to be destroyed at the Emergent BioSolutions manufacturing plant in Baltimore last week because it did not meet the company’s quality standards.

Records obtained by The Baltimore Sun show that the plant has had numerous problems, including “deficient” space to prevent contamination, insufficient employee training, and lack of standardization for quality-control measures.

Maryland Gov. Larry Hogan called the reduction a “big hit” and said that the nation’s governor’s were blindsided when the White House told them they were seeing a drop in vaccine availability.

“We really still don’t know how it happened,” Hogan told reporters Friday afternoon. “It’s very frustrating. We were told by the White House COVID taskforce that we wouldn’t have any more issues.”

The vaccine maker is expecting to fulfill its 100-million dose commitment to the U.S. by the end of May, a federal health official told the Sun.

“I think we’re all a little bit in the dark here,” Danny Avula, Virginia’s vaccine coordinator, told reporters Friday. “We’re hopeful that by the end of April it will pick back up to what we expected to receive in that 100,000 to 150,000 doses in that state allocation in Virginia.”

But Hogan expects the J&J vaccine reduction in Maryland to last into May.

“We were hoping with the [vaccine] infrastructure we built to be able to finish huge chunk of this in April and May, and now it’s going to be a little slower in April…that we were prepared for or that they’ve been leading us to believe. Hopefully we’ll be able to catch up in May,” Hogan told reporters Friday.

Hogan added that he’s hopeful the Maryland-based Novavax’s vaccine, with an efficacy of 89.3%, will be submitting its final trial information in late April or early May. Approval would mean another vaccine option for residents.

Meanwhile, in the District Mayor Muriel Bowser announced that the city health department is opening up vaccine appointments to all residents 16 years or older on April 12. Even with the limited supply of J&J vaccines, John Falcicchio, the mayor’s chief of staff, on Friday tweeted “full steam ahead,” while asking residents to pre-register for vaccine appointments.